Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Bevacizumab for Epistaxis in HHT
NCT01397695Phase 2Completed
- Sponsor
- University of California, San Diego
- Start
- Jun 2009
- Primary completion
- Jan 2014
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab in hereditary hemorrhagic telangiectasia (HHT), sponsored by University of California, San Diego. Primary endpoints: Epistaxis Severity Score at 24 months, Hematocrit at 6 months and 2 more. Started Jun 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT01397695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01397695.